Why Vertex Pharmaceuticals' Shares Rose 2.8% in September

[cafead]

via

• Vertex, known for its cystic fibrosis therapies, is branching out into gene-editing therapies for rare genetic blood disorders.
• The company’s revenue was up in the second quarter by 12% year over year.
• Vertex’s cystic fibrosis drug, Trikafta, is helping the company bankroll research and development.

article source